Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?

Edit Your Profile

Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery? Other Scholarly Work

cited authors

Runowicz, Carolyn

sustainable development goals

authors

Runowicz, Carolyn

publication date

August 1, 2006

webpage

https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239341100003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=e451fd656366bf1ec5554941920a9ccb

published in

Nature Clinical Practice Oncology Journal

keywords

CARBOPLATIN
CISPLATIN
GYNECOLOGIC-ONCOLOGY-GROUP
Life Sciences & Biomedicine
Oncology
PACLITAXEL
PHASE-III TRIAL
Science & Technology
cisplatin
intraperitoneal therapy
ovarian cancer
paclitaxel
survival

WoS ID

000239341100003

Digital Object Identifier (DOI)

https://doi.org/10.1038/ncponc0556

start page

416

end page

417

volume

3

issue

8